Editor's Notes: New drugs in this article refer to
Innovative/improved new chemical drugs / biological products that have never been granted marketing authorization in or outside China;
Original/improved chemical drugs / biological products that have received marketing authorization outside China and are applying for marketing authorization in China;
First generic drugs in China*.
*"First generic drug in China" refers to the first generic drug developed by a Chinese company and approved by China National Medical Products Administration (NMPA) with marketing authorization.
Related Articles:
In June 2022, China NMPA approved 25 new drugs, including 17 chemical drugs and 8 biological products.
1. Jiangsu Hengrui Pharmaceuticals' SHR3680 Tablets;
2. Bayer's Finerenone Film-coated Tablets (Kerendia);
3. Qilu Pharmaceutical's Aripiprazole Oral Soluble Film;
4. Qilu Pharmaceutical's Memantine Hydrochloride Oral Soluble Film;
5. Boehringer Ingelheim's Empagliflozin Tablets;
6. Jiangsu Hengrui Pharmaceuticals' Pyrotinib Maleate Tablets;
7. Shenzhen China Resources Gosun Pharmaceutical's Mitoxantrone Hydrochloride Injection for Tracing;
8. Shanghai Allist Pharmaceuticals' Furmonertinib Mesilate Tablets;
9. Hebei Renhe Yikang Pharmaceutical's Levetiracetam in Sodium Chloride Injection;
10. Sichuan Baili Pharmaceutical's Enalapril Maleate Oral Solution;
11. Chengdu Suncadia Medicine's Tacrolimus Extended-release Capsules;
12. Shijizhuang No. 4 Pharmaceutical's Blonanserin Tablets;
13. EyePoint Pharmaceuticals' Fluocinolone Acetonide Intravitreal Implants (YUTIQ);
14. Basilea Pharmaceutica's Isavuconazonium Sulfate for Injection (CRESEMBA);
15. Italfarmaco's Riluzole Oral Suspension (TIGLUTIK);
16. Laboratorios Farmaceuticos' Bemiparin Sodium Injection;
17. Bayer's Larotrectinib Sulfate Oral Solution;
18. CStone Pharmaceuticals' Sugemalimab Injection;
19. Akeso Biopharma's Cadonilimab Injection;
20. Innovent Biologics' Sintilimab Injection (Tyvyt);
21. BeiGene's Tislelizumab Injection;
22. BMS's Nivolumab Injection;
23. Merck's Cetuximab Solution for Infusion (Erbitux);
24. GenSci's Recombinant Human Growth Hormone Injection (Jintropin).
25. Gilead Sciences' Sacituzumab Govitecan for Injection (Trodelvy).
Details of the approved drugs are listed as follows.
1. SHR3680 Tablets
1 | Generic Name | SHR3680 Tablets |
2 | Brand Name | / |
3 | Registration Classification | Class 1 chemical drug |
4 | Application Type | New drug application (NDA) |
5 | Marketing Authorization Holder (MAH) | Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
6 | Approval Date | June 30, 2022 |
7 | Time from Application Acceptance to Approval | 239 days |
8 | Priority Review | Yes (breakthrough therapy) |
9 | Target(s) | Androgen receptor |
10 | Indication(s) | Indicated for treating metastatic hormone-sensitive prostate cancer (mHSPC) with high tumor burden. |
2. Finerenone Film-coated Tablets
1 | Generic Name | Finerenone Film-coated Tablets |
2 | Brand Name | Kerendia |
3 | Registration Classification | Class 1 chemical drug |
4 | Application Type | NDA, import |
5 | MAH | Bayer AG |
6 | Approval Date | June 30, 2022 |
7 | Time from Application Acceptance to Approval | 510 days |
8 | Priority Review | No |
9 | Target(s) | Nuclear Receptor Subfamily 3 Group C Member 2 (NR3C2) |
10 | Indication(s) | Indicated to reduce the risk of sustained eGFR decline and end-stage kidney disease in adult patients (with an estimated glomerular filtration rate (eGFR) of 25-75 ml/min/1.73m2 together with albuminuria) with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). |
3. Aripiprazole Oral Soluble Film
1 | Generic Name | Aripiprazole Oral Soluble Film |
2 | Brand Name | / |
3 | Registration Classification | Class 2.2 chemical drug |
4 | Application Type | NDA |
5 | MAH | Qilu Pharmaceutical Co., Ltd. |
6 | Approval Date | June 24, 2022 |
7 | Time from Application Acceptance to Approval | 603 days |
8 | Priority Review | No |
9 | Target(s) | 5-hydroxytryptamine receptor 1A (HTR1A); 5-hydroxytryptamine receptor 2a (HTR2A); D(2) dopamine receptor (DRD2) |
10 | Indication(s) | Indicated for treating schizophrenia. |
4. Memantine Hydrochloride Oral Soluble Film
1 | Generic Name | Memantine Hydrochloride Oral Soluble Film |
2 | Brand Name | / |
3 | Registration Classification | Class 2.2 chemical drug |
4 | Application Type | NDA |
5 | MAH | Qilu Pharmaceutical Co., Ltd. |
6 | Approval Date | June 24, 2022 |
7 | Time from Application Acceptance to Approval | 582 days |
8 | Priority Review | No |
9 | Target(s) | NMDA receptor |
10 | Indication(s) | Indicated for treating moderate to severe dementia of the Alzheimer's type. |
5. Empagliflozin Tablets
1 | Generic Name | Empagliflozin Tablets |
2 | Brand Name | Jardiance |
3 | Registration Classification | Class 2.4 chemical drug |
4 | Application Type | NDA, import |
5 | MAH | Boehringer Ingelheim International GmbH |
6 | Approval Date | June 10, 2022 |
7 | Time from Application Acceptance to Approval | 566 days |
8 | Priority Review | No |
9 | Target(s) | Sodium/glucose cotransporter 2 (SLC5A2) |
10 | Indication(s) | Previously approved:
Limitation of use: the drug is not recommended in patients with type 1 diabetes mellitus or diabetic ketoacidosis.
Newly approved on June 10, 2022: Indicated in adults with heart failure and reduced ejection fraction. |
6. Pyrotinib Maleate Tablets
1 | Generic Name | Pyrotinib Maleate Tablets |
2 | Brand Name | Ai Rui Ni (艾瑞妮) |
3 | Registration Classification | Class 2.4 chemical drug |
4 | Application Type | NDA |
5 | MAH | Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
6 | Approval Date | June 2, 2022 |
7 | Time from Application Acceptance to Approval | 258 days |
8 | Priority Review | Yes (conditional approval) |
9 | Target(s) | Epidermal growth factor receptor (EGFR); Human epidermal growth factor receptor 2 (HER2) |
10 | Indication(s) | Previously approved: This drug, in combination with capecitabine, is indicated for the treatment of HER2-positive patients with recurrent or metastatic breast cancer no matter the patients have received trastuzumab treatment or not. Patients are required to have received anthracycline or taxane chemotherapy before taking Pyrotinib Maleate Tablets. The indication is conditionally approved based on the results of a phase II clinical trial involving 128 patients with the indication. Full approval will depend on the ongoing confirmatory trial's verification of the drug's clinical benefit in this patient group.
Approved on June 2, 2022: This drug, combined with trastuzumab and docetaxel, is indicated as a neoadjuvant therapy for patients with HER2-positive early/locally advanced breast cancer. |
7. Mitoxantrone Hydrochloride Injection for Tracing
1 | Generic Name | Mitoxantrone Hydrochloride Injection for Tracing |
2 | Brand Name | / |
3 | Registration Classification | Class 2.4 chemical drug |
4 | Application Type | NDA |
5 | MAH | Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. |
6 | Approval Date | June 10, 2022 |
7 | Time from Application Acceptance to Approval | 272 days |
8 | Priority Review | No |
9 | Target(s) | DNA Topoisomerase II Alpha (TOP2A) |
10 | Indication(s) | Indicated for tracing tumor-draining lymph nodes around thyroid tumor and other tumors. |
8. Furmonertinib Mesilate Tablets
1 | Generic Name | Furmonertinib Mesilate Tablets |
2 | Brand Name | Ai Fu Sha (艾弗沙) |
3 | Registration Classification | Class 2.4 chemical drug |
4 | Application Type | NDA |
5 | MAH | Shanghai Allist Pharmaceuticals Co., Ltd. |
6 | Approval Date | June 30, 2022 |
7 | Time from Application Acceptance to Approval | 193 days |
8 | Priority Review | Yes (breakthrough therapy) |
9 | Target(s) | EGFR T790M |
10 | Indication(s) | Previously approved: Indicated for treating adult patients with locally advanced or metastatic NSCLC with disease progression during or after prior EGFR-TKI therapy, and confirmed by testing to be positive for EGFR T790M mutation.
Newly approved on June 30, 2022: In combination with trastuzumab and docetaxel, the drug is indicated as neoadjuvant therapy for patients with HER2-positive early/locally advanced breast cancer. |
9. Levetiracetam in Sodium Chloride Injection
1 | Generic Name | Levetiracetam in Sodium Chloride Injection |
2 | Brand Name | / |
3 | Registration Classification | Class 3 chemical drug |
4 | Application Type | Abbreviated new drug application (ANDA) |
5 | MAH | Hebei Renhe Yikang Pharmaceutical Co., Ltd. |
6 | Approval Date | June 20, 2022 |
7 | Time from Application Acceptance to Approval | 463 days |
8 | Priority Review | No |
9 | Target(s) | Synaptic vesicle glycoprotein 2A (SV2A) |
10 | Indication(s) |
|
11 | Notes | First generic drug in China |
10. Enalapril Maleate Oral Solution
1 | Generic Name | Enalapril Maleate Oral Solution |
2 | Brand Name | / |
3 | Registration Classification | Class 3 chemical drug |
4 | Application Type | ANDA |
5 | MAH | Sichuan Baili Pharmaceutical Industry Co., Ltd. |
6 | Approval Date | June 30, 2022 |
7 | Time from Application Acceptance to Approval | 515 days |
8 | Priority Review | No |
9 | Target(s) | Angiotensin-converting enzyme (ACE) |
10 | Indication(s) |
|
11 | Notes | First generic drug in China |
11. Tacrolimus Extended-release Capsules
1 | Generic Name | Tacrolimus Extended-release Capsules |
2 | Brand Name | / |
3 | Registration Classification | Class 4 chemical drug |
4 | Application Type | ANDA |
5 | MAH | Chengdu Suncadia Medicine Co., Ltd. |
6 | Approval Date | June 30, 2022 |
7 | Time from Application Acceptance to Approval | 561 days |
8 | Priority Review | No |
9 | Target(s) | Calcineurin subunit B type 2 (PPP3R2) |
10 | Indication(s) | Indicated for
|
11 | Notes | First generic drug in China |
12. Blonanserin Tablets
1 | Generic Name | Blonanserin Tablets |
2 | Brand Name | / |
3 | Registration Classification | Class 4 chemical drug |
4 | Application Type | ANDA |
5 | MAH | Shijizhuang No. 4 Pharmaceutical Co., Ltd. |
6 | Approval Date | June 20, 2022 |
7 | Time from Application Acceptance to Approval | 498 days |
8 | Priority Review | No |
9 | Target(s) | 5-hydroxytryptamine 2 receptor (5-HT2); D(2) dopamine receptor (DRD2) |
10 | Indication(s) | Indicated for the treatment of schizophrenia. |
11 | Notes | First generic drug in China |
13. Fluocinolone Acetonide Intravitreal Implants
1 | Generic Name | Fluocinolone Acetonide Intravitreal Implants |
2 | Brand Name | YUTIQ |
3 | Registration Classification | Class 5.1 chemical drug |
4 | Application Type | NDA, import |
5 | MAH | EyePoint Pharmaceuticals, Inc. |
6 | Approval Date | June 20, 2022 |
7 | Time from Application Acceptance to Approval | 435 days |
8 | Priority Review | No |
9 | Target(s) | / |
10 | Indication(s) | Indicated for the treatment of chronic non-infectious uveitis. |
14. Isavuconazonium Sulfate for Injection
1 | Generic Name | Isavuconazonium Sulfate for Injection |
2 | Brand Name | CRESEMBA |
3 | Registration Classification | Class 5.1 chemical drug |
4 | Application Type | NDA, import |
5 | MAH | Basilea Pharmaceutica Deutschland GmbH |
6 | Approval Date | June 20, 2022 |
7 | Time from Application Acceptance to Approval | 712 days |
8 | Priority Review | No |
9 | Target(s) | Lanosterol 14-alpha demethylase (CYP51A1) |
10 | Indication(s) | The drug is a new antifungal therapy indicated for treating invasive mucormycosis and/or aspergillosis in adult patients. |
15. Riluzole Oral Suspension
1 | Generic Name | Riluzole Oral Suspension |
2 | Brand Name | TIGLUTIK |
3 | Registration Classification | Class 5.1 chemical drug |
4 | Application Type | NDA, import |
5 | MAH | Italfarmaco, S.A. |
6 | Approval Date | June 2 |
7 | Time from Application Acceptance to Approval | 874 days |
8 | Priority Review | No |
9 | Target(s) | Metabotropic glutamate receptor 1 (GRM1); Sodium channel |
10 | Indication(s) | Indicated for treating amyotrophic lateral sclerosis (ALS). |
16. Bemiparin Sodium Injection
1 | Generic Name | Bemiparin Sodium Injection |
2 | Brand Name | HIBOR (稀保) |
3 | Registration Classification | Class 5.1 chemical drug |
4 | Application Type | NDA, import |
5 | MAH | Laboratorios Farmaceuticos ROVI, S.A. |
6 | Approval Date | June 24, 2022 |
7 | Time from Application Acceptance to Approval | 295 days |
8 | Priority Review | No |
9 | Target(s) | Serpin Family C Member 1 (SERPINC1) |
10 | Indication(s) | The drug is indicated for
|
17. Larotrectinib Sulfate Oral Solution
1 | Generic Name | Larotrectinib Sulfate Oral Solution |
2 | Brand Name | Vitrakvi |
3 | Registration Classification | Class 5.1 chemical drug |
4 | Application Type | NDA, import |
5 | MAH | Bayer AG |
6 | Approval Date | June 24, 2022 |
7 | Time from Application Acceptance to Approval | 399 days |
8 | Priority Review | Yes (pediatric drug) |
9 | Target(s) | Neurotrophic Receptor Tyrosine Kinase 1 (NTRK1) |
10 | Indication(s) | The drug is indicated for treating solid tumors harboring NTRK gene fusions in pediatric and adult patients who have locally advanced or metastatic disease, or may have serious complications due to surgical resection, or don't have satisfactory therapy. |
18. Sugemalimab Injection
1 | Generic Name | Sugemalimab Injection |
2 | Brand Name | Cejemly (择捷美) |
3 | Registration Classification | Class 1 therapeutic biological product |
4 | Application Type | Biologics License Application (BLA) |
5 | MAH | CStone Pharmaceuticals |
6 | Approval Date | June 2, 2022 |
7 | Time from Application Acceptance to Approval | 267 days |
8 | Priority Review | No |
9 | Target(s) | Programmed death-ligand 1 (PD-L1) |
10 | Indication(s) | Previously approved:
Newly approved on June 2, 2022:
|
19. Cadonilimab Injection
1 | Generic Name | |
2 | Brand Name | Kai Tan Ni (开坦尼) |
3 | Registration Classification | Class 1 therapeutic biological product |
4 | Application Type | BLA |
5 | MAH | Akeso Biopharma Co., Ltd. |
6 | Approval Date | June 30, 2022 |
7 | Time from Application Acceptance to Approval | 275 days |
8 | Priority Review | Yes (conditional approval) |
9 | Target(s) | PD-1 |
10 | Indication(s) | Indicated for treating recurrent or metastatic cervical cancer patients with prior failure of platinum-based chemotherapy. |
20. Sintilimab Injection
1 | Generic Name | Sintilimab Injection |
2 | Brand Name | Tyvyt (达伯舒) |
3 | Registration Classification | Class 2.2 therapeutic biological product |
4 | Application Type | BLA |
5 | MAH | Innovent Biologics, Inc. |
6 | Approval Date | June 20, 2022 |
7 | Time from Application Acceptance to Approval | 267 days |
8 | Priority Review | No |
9 | Target(s) | PD-1 |
10 | Indication(s) | Previously approved indications:
Newly approved on June 20, 2022:
|
21. Tislelizumab Injection
1 | Generic Name | Tislelizumab Injection |
2 | Brand Name | Bai Ze An (百泽安) |
3 | Registration Classification | Class 2.2 therapeutic biological product |
4 | Application Type | BLA |
5 | MAH | BeiGene (Shanghai) Biotechnology Co., Ltd. |
6 | Approval Date | June 10, 2022 |
7 | Time from Application Acceptance to Approval | 291 days |
8 | Priority Review | No |
9 | Target(s) | PD-1 |
10 | Indication(s) | Previously approved:
Newly approved on June 10, 2022:
|
22. Nivolumab Injection
1 | Generic Name | Nivolumab Injection |
2 | Brand Name | OPDIVO (欧狄沃) |
3 | Registration Classification | Class 2.1 & 3.3 therapeutic biological product |
4 | Application Type | BLA, import |
5 | MAH | Bristol-Myers Squibb Pharma EEIG |
6 | Approval Date | June 24, 2022 |
7 | Time from Application Acceptance to Approval | 280 days |
8 | Priority Review | No |
9 | Target(s) | PD-1 |
10 | Indication(s) | Previously approved:
Newly approved on June 24, 2022:
|
23. Cetuximab Solution for Infusion
1 | Generic Name | Cetuximab Solution for Infusion |
2 | Brand Name | Erbitux (爱必妥) |
3 | Registration Classification | Class 3.1 therapeutic |
4 | Application Type | BLA, import |
5 | MAH | Merck Europe B.V. |
6 | Approval Date | June 20, 2022 |
7 | Time from Application Acceptance to Approval | 225 days |
8 | Priority Review | No |
9 | Target(s) | EGFR |
10 | Indication(s) | Previously approved:
Newly approved on June 20, 2022:
|
24. Recombinant Human Growth Hormone Injection
1 | Generic Name | Recombinant Human Growth Hormone Injection |
2 | Brand Name | Jintropin (赛增) |
3 | Registration Classification | Class 3.2 therapeutic biological product |
4 | Application Type | BLA |
5 | MAH | GeneScience Pharmaceuticals Co., Ltd. (GenSci) |
6 | Approval Date | June 30, 2022 |
7 | Time from Application Acceptance to Approval | 252 days |
8 | Priority Review | No |
9 | Target(s) | / |
10 | Indication(s) | Previously approved:
Newly approved on June 30, 2022:
|
25. Sacituzumab Govitecan for Injection
1 | Generic Name | Sacituzumab Govitecan for Injection |
2 | Brand Name | Trodelvy |
3 | Registration Classification | Class 3.1 therapeutic biological product |
4 | Application Type | BLA, import |
5 | MAH | Gilead Sciences, Inc. |
6 | Approval Date | June 10, 2022 |
7 | Time from Application Acceptance to Approval | 385 days |
8 | Priority Review | Yes (conditional approval) |
9 | Target(s) | / |
10 | Indication(s) | Indicated for treating adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more systemic therapies (at least one of which was targeted at metastatic diseases). |
Read More
Contact BaiPharm to know more about drug marketing authorization in China.